Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Search in:

Advanced search

Current Medical Research and Opinion Volume 39, 2023 - Issue 8

Submit an article Journal homepage

Open access

2,297

Views

CrossRef citations to date

Altmetric

Diabetes

Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates

Signe Baattrup Reitzela Department of Economics, EY Denmark, Frederiksberg, Denmark

https://orcid.org/0000-0002-2839-4510

Mette Bøgelunda Department of Economics, EY Denmark, Frederiksberg, Denmark

https://orcid.org/0000-0003-0866-9414

Amaury Basseb Middle East & Africa, Novo Nordisk Region South East Europe, Zurich, Switzerland

https://orcid.org/0009-0006-2412-8799

Olga Barszczewskab Middle East & Africa, Novo Nordisk Region South East Europe, Zurich, Switzerland

https://orcid.org/0000-0002-5953-7414

Hongye Renc Middle East & Africa, Novo Nordisk Region North West Europe, Copenhagen S, DenmarkCorrespondence[email protected]

https://orcid.org/0000-0003-0080-4765

Pages 1055-1060 | Received 01 Jun 2023, Accepted 27 Jun 2023, Published online: 10 Jul 2023

Cite this article
https://doi.org/10.1080/03007995.2023.2231275
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Hussain A. Al-Omar, Hind S. Almodaimegh, Abubker Omaer, Lamya M. Alzubaidi, Bandar Al-Harbi, Ibtisam Al-Harbi, Mohamed Hassan & Omar Akhtar. (2024) Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia. Journal of Medical Economics 27:1, pages 418-429.
Read now

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references